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Table 1
Sample size estimated for efﬁcacy trials with different treatment effects, trial
lengths, and biomarker metrics. Trials included visits of 3, 6, 12 or 24 months up to
stated trial length, except 6 & 12 month which is a 12 month trial with no 3 month
visit. Averaged regions were all regions, or 4 regions with most positive (Top 4) or
most negative (Bottom 4) change
Avg magnitude
of change inAverage change in
Treatment Trail length All Top 4 Bottom 4 All Top 4
Partial stop 24 Months >50000 256 326 95 109
12 Months 9788 254 450 103 106
6 & 12 Months 8958 204 415 87 102
6 Months 9038 310 698 138 143
2% Growth 24 Months 76 927 67 281 212
12 Months 259 10765 107 158 140
6 & 12 Months 195 21745 96 144 140
6 Months 828 1696 204 171 161
5% Growth 24 Months 13 32 21 58 1419
12 Months 35 197 35 15084 1084
6 & 12 Months 27 124 31 1123 2410
6 Months 96 1590 72 647 350
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EFFICACY TRIALS FOR KNEE CARTILAGE CHANGE MAY ACHIEVE
REASONABLE TREATMENT GOALS IN£12 MONTHS AND SAMPLE
SIZE£200/ARM
R. Buck y, M-P. Hellio Le Graverand z, W. Wirth x, F. Eckstein x,k.
y StatAnswers Consulting LLC, Minneapolis, MN, USA; z Pﬁzer Global Res.
and Dev., New London, CT, USA; xChondrometrics GmbH, Ainring,
Germany; k Inst. of Anatomy, Paracelsus Med. Univ., Salzburg, Austria
Purpose: The choice of an efﬁcacy biomarker for cartilage change in a
clinical trial for structural treatment of osteoarthritis depends on
expected treatment effects, disease progression patterns, and trial
length. Previous work has shown that local increases and decreases in
cartilage thickness in study participants may occur over short periods of
time. Presumably treatment would minimize both thinning and thick-
ening aspects of disease progression, but could also lead to localized or
global cartilage growth. Hence simple averaging of cartilage loss across
joint compartments or cartilage plates may not efﬁciently capture the
complexity of thickness change, likely to be seen in shorter clinical
trials. This study examines different metrics of cartilage thickness
change for clinical trials under different trial lengths and treatment
effects.
Methods: Estimations of sample size (N) for clinical trials were based
on differences in cartilage thickness change observed in coronal MR
images (3 Tesla) of 145 women (71 with medial radiographic osteo-
arthritis (ROA), 74 with no symptoms or ROA) at baseline, 3, 6, 12 and 24
months of an observational trial. Femorotibial cartilage thickness was
determined across 5 tibial and 3 femoral subregions in each (medial/
lateral) compartment. Sample size per arm (treatment, control, two-
sample t-test) was used to measure the efﬁciency of different clinical
trial and biomarker choices. Three treatment effects were considered:
disease progression, the mean difference in change between ROA and
asymptomatic subjects, is reduced by 50%, and global growth of 2% or
5%. Two trial parameters were explored: trial length (3, 6, 12 or 24
months), and whether a single or multiple visits were included in the
statistical analysis. All biomarkers considered were univariate, i.e., they
summarized change frommultiple regions and visits into a single value
per subject. Other biomarker parameters examined: use of thickness
change (c) or magnitude (absolute value) of change (jcj); choice of
regions (all, medial, central or external (C/E) medial regions or C/E
medial regions individually or choice dependent on magnitude of
change); methods of summarizing over regions and visits (average,
maximum or minimum).
Results: Multi-visit metrics had smaller N than single visit metrics. A 3
month visit was not informative; N for 3 month trials were large, N >
325 and was typically more than twice as large as needed at 6 months;
and including a 3 month visit did not reduce N in multi-visit metrics.
Biomarkers averaging all or just medial regions had smaller N than
individual regions or the average of the C/E medial regions. Table 1
reports results for biomarkers that consistently had small N across
visits for at least one of the treatment effects. Averages of the regions
with the most positive or most negative changes were often the most
efﬁcient biomarkers, but how these changes were included depended
on treatment scenario. When the treatment slowed cartilage disease
progression, trials using jcj had smaller sample sizes (87 < N < 166)
than using thickness change, c (N > 168) regardless of trial length. On
the other hand, with global 5% growth, biomarkers based on c were
estimated to have much smaller sample sizes (N< 100) than when
based on jcj (N > 300), except when average jcj over all regions in 24
month trials (N ¼ 58). The most efﬁcient change biomarkers under 5%
global growth were the average of all regions and, perhaps surpris-
ingly, the average of the 4 most negative changes. Biomarkers based on
c and jcj are nearly comparable for 2% growth treatment scenario. The
average of regions with the most negative changes, c, (67 < N < 204)
was more efﬁcient than using average of regions with largest magni-
tude jcj (140 < N < 212), but not by much and was slightly worse for a
6 month trial.
Conclusions: Efﬁcacy trials for cartilage change of 6 or 12 months may
achieve reasonable treatment goals with sample sizes < 200/arm.
Generally the most efﬁcient cartilage thickness biomarkers were those
that measured the largest negative changes or the largest changes in
absolute value, but the choice between these biomarkers depended on
trial length and expected treatment beneﬁt.108
AGGRECAN FRAGMENTOLOGY – PATTERN OF AGGRECAN
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Purpose: Aggrecan, the main proteoglycan in cartilage extracellular
matrix, is proteolysed in joint injuries and in osteoarthritis. The main
proteases digesting aggrecan are the matrix metalloproteases (MMPs)
and aggrecanases, but aggrecan can also be cleaved by calpains and
cathepsins. The question that we asked was: is there a speciﬁc pro-
teolytic aggrecan fragmentation pattern (aggrecan fragmentology)
which depends on disease and/or disease development?
Methods: Synovial ﬂuid (SF) from subject groups was pooled: knee
healthy reference (n ¼ 10; age range ¼ 19-58 years), adult knee injuries
(n¼ 64;mean age¼ 33 years), juvenile knee injuries (n¼ 9; age range¼
12-15 years), osteoarthritis (OA, n ¼ 47; mean age ¼ 48 years), and
juvenile idiopathic arthritis (JIA, n ¼ 120; age range ¼ 13-19 years). The
total sulphated glycosaminoglycan was analysed in the SF-pools by
Alcian blue precipitation, and the values were converted to total
aggrecan using an assumption that the aggrecanMw¼ 1500 000 g/mol
and that 75% of the Mw comes from the glycosaminoglycan’s. Aggrecan
fragments were puriﬁed from the SF-pools using CsCl density gradient
centrifugation collecting the SF-D1 fractions. Puriﬁed calf aggrecan
(A1D1 fraction from CsCl density gradient centrifugation) was used as
full length G1-G3 standards for Western blot quantiﬁcations, and total
degradation of puriﬁed human aggrecan (A1D1 fraction) was used to
make ARGS (aggrecanase-1 digest), FFGV (MMP-3 digest) and PGVA (m-
calpain digest) standards. The standards and the SF-D1 samples were
deglycosylated and visualized by Western blot using anti-aggrecan
neoepitope antibodies ARGS, FFGV, PGVA and an anti-aggrecan G3
antibody. Total amount (mean pmol) of ARGS, FFGV, G1-G3, inter
globular domain (IGD)-PGVA and chondroitin sulfate region 2 (CS2)-G3
fragments was calculated (using Western blot and standards) for each
subject group, and the proportion of fragments (% of aggrecan) was
calculated in relation to the total amount of fragments detected in each
group.
Results: The total amount aggrecan detected in the SF pools was
approximately 2-3 higher in the knee injury groups (adult and juvenile
injury) and in the OA group (101 – 129 pmol/ml) compared to the knee
healthy reference and the JIA groups (44 and 45 pmol/ml). The dis-
tribution of full length aggrecan (G1-G3) and of aggrecanase (ARGS and
CS-G3), MMP (FFGV) and calpain (IGD-PGVA) generated fragments was
different between patient groups (Fig. 1). Of the total amount of frag-
ments detected, calpain generated PGVA fragments was low in the
different patients groups, although the reference group contained 7%
PGVA fragments. The adult and juvenile injury groups and the OA group
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the reference and the JIA groups had high proportion of CS2-G3 frag-
ments (53 and 52%, respectively). Estimates of the relative mol-mol
proportions of the pathological aggrecanase cleavage in the IGD gen-
erating ARGS-fragment and the aggrecanase turnover cut in the CS2
region generating CS2-G3 fragments showed that the ARGS proportion
was 27% for the reference group while it was between 69 and 82% in the
adult and juvenile injury groups and in OA group. A similar comparison
of MMP generated FFGV (a cut in the IGD of aggrecan) and the aggre-
canase generated ARGS fragments showed that the FFGV fragments
amounted to 32% for the reference group while the proportion was
much lower for the adult injury (2.1%), juvenile injury (7.3%) and the OA
(1.2%) groups.Fig 1. Proportion (mol/mol) of full length aggrecan (G1-G3), aggrecanase
generated ARGS and CS2-G3 fragments, MMP generated FFGV fragments
and calpain generated IGD-PGVA fragments found in synovial ﬂuid pools
of different patient Groups.Conclusions: The OA, juvenile and adult knee injury groups show
similar aggrecan fragmentation patterns, which differ from the frag-
mentation pattern of JIA and knee healthy reference groups. This sug-
gests that the aggrecan fragmentation patterns are different between
different joint diseases. This information supports further under-
standing of mechanisms of cartilage damage in these conditions, and
may aid to distinguish different patient groups.
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RELATIONSHIP BETWEEN CONCOMITANT INJURIES SUSTAINED
DURING ACL RUPTURE AND BIOLOGICAL MARKERS OF ARTICULAR
CARTILAGE METABOLISM
S.M. Wasilko y, T.W. Tourville y, M.J. DeSarno y, J.R. Slauterbeck y,
R.J. Johnson y, A. Struglics z, B.D. Beynnon y. yUniv. of Vermont Coll. of
Med., Burlington, VT, USA; z Lund Univ., Dept. of Orthopaedics, Clinical
Sci., Lund, Sweden
Purpose: There is limited information regarding the onset and earliest
stages of post-traumatic osteoarthritis (OA), which is commonly asso-
ciated with rupture of the anterior cruciate ligament (ACL). Con-
sequently, the purpose of this investigation was to examine
relationships between concomitant injuries to the tibiofemoral articu-
lar cartilage sustained during acute ACL injury with patient-oriented
outcomes as well as biochemical markers of type II collagenmetabolism
and aggrecan degradation, compared to healthy, matched controls.
Methods: Thirty-nine ACL-reconstructed (20 women) and 32 knee
healthy control (18women) subjectsmatched for age, sex, race, BMI, and
activity level were evaluated in this cross-sectional study. Inclusion
criteria for injured subjects was: age 14-55yrs, BMI between 18.5-30,
Tegner activity score  5, no previous knee pathologies, normal ana-
tomic tibiofemoral alignment, < 2/3 meniscectomy performed at sur-
gery, and  grade 3A articular cartilage lesions (based on International
Cartilage Repair Society [ICRS] classiﬁcation). Similar inclusion criteria
were utilized for controls with the exception of: no history of knee pain
or dysfunction, normal clinical knee examination, and no abnormalitieson MRI. Articular cartilage lesions were identiﬁed under direct arthro-
scopic visualization at the time of ACL reconstruction and were docu-
mented by one of two sports medicine fellowship-trained orthopaedic
surgeons. Injured subjects were classiﬁed as low-risk for future OA
development if they displayed  grade 2 articular cartilage lesions.
Injured subjectswere classiﬁed as high-risk for futureOAdevelopment if
they displayed grade 3A articular cartilage lesions. Synovial ﬂuid sam-
ples were obtained from injured subjects immediately prior to surgery,
and from controls at a single time point. The mean interval between
index injury and surgery date was 70.1 days; range: 18-155 days. Syno-
vial ﬂuid markers of type II collagen synthesis were evaluated by
measuring concentrations of procollagen II C-propeptide (CPII) with
ELISA (Ibex).Markers of type II collagen degradationwere also evaluated
with ELISA and included collagen type II cleavage product (C2C; Ibex)
and collagen type I and II cleavage product (C1,2C; Ibex). Additionally,
the Alanine-Arginine-Glycine-Serine (ARGS) neoepitope was measured
as amarkerof aggrecandegradationusing an electrochemiluminescence
in-house immunoassay. Patient oriented outcomeswere evaluated in all
subjects with the Knee Injury and Osteoarthritis Outcome Score (KOOS).
Analysis of Variance was performed for statistical evaluation.
Results: Of the 39 ACL reconstructed individuals, 29 (74%) had articular
cartilage injuries that were grade 2 or less, while 10 (26%) had grade 3A
articular cartilage injuries. Controlling for sex, BMI, activity level, and
time between injury and baseline measurements, there were no sig-
niﬁcant differences in mean levels of markers of type II collagen
metabolism or aggrecan breakdown (p ¼ 0.48 and p ¼ 0.55, respec-
tively) between risk groups. Associations between ARGS concentration
and KOOS subscales of symptoms and pain were found to be sig-
niﬁcantly different between groups (p ¼ 0.03 and p ¼ 0.01, respec-
tively). These signiﬁcant interactions were driven by positively
correlated associations between KOOS scores and ARGS concentration
for the high risk group, and negatively correlated associations between
KOOS scores and ARGS concentration for the low risk group.
Conclusions: In ACL injured subjects with concomitant grade 3A
articular cartilage injuries, levels of synovial ﬂuid ARGS were directly
associated with improvements in KOOS symptoms and pain. As a sec-
ondary analysis of a longitudinal investigation, this study provides
preliminary, hypothesis generating data and may not be adequately
powered to elucidate true differences in biomarker concentrations
between these groups. Nevertheless, our statistically signiﬁcant ﬁnd-
ings may suggest the involvement of synovial ﬂuid ARGS in a localized
tissue repair response involving an increase in the synthesis of aggrecan
following traumatic knee injury.
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CARTILAGE COLLAGEN NEOEPITOPE C2C AND CLINICAL
PARAMETERS IN MIDDLE-AGED PATIENTS WITH KNEE PROBLEMS.
CORRELATIONS OF URINARY OUTPUT OF C2C WITH CARTILAGE
LESIONS, KOOS VALUES AND FUNCTIONAL ABILITIES OF LOWER
LIMB
A.O. Tamm y, J. Kumm y, A. Tamm y, M. Lintrop y, A. Kukner y, T. Saluse z,
L. Rips z, T. Tein z, A. Pintsaar z, A. Kukner z. yUniv. of Tartu, Tartu, Estonia;
z Tartu Univ. Hosp., Tartu, Estonia
Purpose: Intensive research in the last decade has demonstrated that
protein biomarkers are required for different purposes in early osteo-
arthritis (OA): to detect OA, to prognose its progression, to assess efﬁcacy
of intervention, etc. Although several biomarkers have acquired deﬁnite
position in the ﬁeld, none of the biomarkers applied up to now can sufﬁ-
ciently discriminate individual or limited number of patients (Labefer, van
Spil, 2013). One of the likelyways to proceed is to investigate neoepitopes.
A collagen type II neoepitope C2C was developed for this purpose.
The aims of the study were to test: (i) the biomarker’s ability to dif-
ferentiate between patients with and without knee cartilage lesion, (ii)
if there is any correlation between urinary C2C output and clinical
status of patients with early knee osteoarthritis, (iii) preferable option
to express results (ng/mmol of creatinine or pg/ml of urine).
Material and methods: We investigated 180 knee OA patients (68
male, 112 female) aged 36-62 (mean 50) yrs. For 112 patients the pro-
gression of the knee OA during the past 3 years was available. Stand-
ardised radiographs of the tibiofemoral(TF) and patello[[Unsupported
Character – Codename -]]femoral(PF) joints were assessed. Radio-
graphic progression was deﬁned as: (i)presence of osteophytes and/or
joint space narrowing (JSN) in subjects with no previous radiographic
OA or (ii)increase in their grade.
